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Abstract
The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza 
vaccination for all persons in the United States aged ≥ 6 months. On June 25, 2014, ACIP 
preferentially recommended live attenuated influenza vaccine (LAIV) for healthy children aged 2–
8 years [1]. Little is known about national LAIV uptake. To determine uptake of LAIV relative to 
inactivated influenza vaccine, we analyzed vaccination records from six immunization information 
system sentinel sites (approximately 10% of U.S. population). LAIV usage increased over time in 
all sites. Among children 2–8 years of age vaccinated for influenza, exclusive LAIV usage in the 
collective sentinel site area increased from 20.1% (2008–09 season) to 38.0% (2013–14). During 
2013–14, at least half of vaccinated children received LAIV in Minnesota (50.0%) and North 
Dakota (55.5%). Increasing LAIV usage suggests formulation acceptability, and this preexisting 
trend offers a favorable context for implementation of ACIP’s preferential recommendation.
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Introduction
The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza 
vaccination for all persons in the United States aged ≥6 months. Two comparative studies 
have reported that the nasal spray formulation (live attenuated influenza virus vaccine, or 
LAIV) confers more protection among children 6 to 71 months of age, compared with the 
injectable formulation (inactivated influenza vaccine, or IIV) [2, 3]. On June 25, 2014, ACIP 
recommended that LAIV be used, when immediately available, for healthy children aged 2–
8 years (e.g., those without chronic medical conditions conferring higher risk for severe 
illness and complications due to influenza). Previously, ACIP stated no preference between 
LAIV and IIV for healthy children aged ≥2 years. This recommendation is expected to result 
in increased uptake of LAIV compared with IIV in otherwise healthy children 2–8 year of 
age, and monitoring the recommendation’s impact will require an understanding of prior 
trends in LAIV usage. LAIV is currently thought to be administered less frequently than IIV, 
although few studies have quantified uptake of the alternate influenza vaccine formulations. 
One pediatric practice-based survey indicated that LAIV composed 30% of influenza 
vaccinations among 2–18 year olds during the 2008–09 influenza season [4]. In order to 
understand pre-recommendation characteristics of LAIV usage, we used population-based 
vaccination surveillance data to assess the relative uptake of LAIV among vaccinated 
children aged 2–8 years in the United States. We additionally assessed LAIV usage among 
children 9–12 years of age; although the ACIP recommendation did not include this age 
group, the impact of the recommendation beyond the targeted ages should be monitored. 
Therefore, we sought to assess preexisting trends in LAIV usage.
Methods
Immunization information systems (IIS) are confidential, population-based systems that 
consolidate data from vaccine providers [5, 6]. IIS sentinel sites, which meet high data 
quality standards and are funded by the Centers for Disease Control and Prevention to 
evaluate vaccine coverage in their populations, are located in Michigan, Minnesota, North 
Dakota, New York City, Oregon (six contiguous counties containing 56% of the Oregon 
population), and Wisconsin [7]. This collective area contains approximately 10% of the 
United States population aged 2–12 years.
IIS sentinel sites queried their respective IIS during April, 2014 to obtain de-identified 
vaccination records for seasonal influenza vaccine doses given during July 1, 2008 to March 
31, 2014 to children born during April 1, 1996 through July 1, 2011. Pandemic influenza 
vaccines were excluded. IIS sentinel sites transmitted record-level data to CDC for analysis. 
We defined influenza vaccination periods as July 1 through March 31 of the following year. 
For each influenza vaccination period, children vaccinated with seasonal influenza vaccine 
were classified as having received LAIV only, IIV only, or any of the following: at least one 
dose of recombinant influenza vaccine, at least one dose of an unknown formulation, or at 
least one dose of more than one formulation. We used SAS®, version 9.3 (SAS Institute, 
Inc.) and Microsoft® Excel® 2010 (Microsoft Corp.) to calculate vaccination coverage using 
2013 Census denominators and percentages of vaccinated children who received LAIV, IIV, 
or both (the latter includes children who received unknown formulations) during each 
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influenza vaccination period. Aggregate measures describe pooled sentinel site vaccination 
records.
Results
Seasonal influenza vaccinations were reported for each influenza vaccination periodduring 
2008–09 through 2013–14 for a mean of 1,179,788 children aged 2–12 years (range: 
885,485–1,347,162) per vaccination period. During this period, overall coverage of ≥1 dose 
of influenza vaccine increased from 29.2% to 39.9% among children 2–8 years of age 
(Figure 1A). During the same period, coverage among children 9–12 years of age was lower, 
and increased from 18.2% to 33.3%.
Among children 2–8 years of age vaccinated for influenza, exclusive use of LAIV increased 
from 20.1% in the 2008–09 vaccination period to 38.0% during the 2013–14 vaccination 
period (Figure 1B). During the latter vaccination period, exclusive LAIV use was highest 
among 5–8 year olds (42.1% of vaccinated children), and lowest among children 2–4 years 
(32.8%) (data not shown). Upward trends in use of LAIV were observed in all six sentinel 
sites, although there was substantial variability between sites. North Dakota, Minnesota, 
Oregon, and Wisconsin had higher LAIV relative uptake (55.5%, 50.0%, 46.1%, and 44.6% 
of children vaccinated for influenza, respectively) than Michigan and New York City (32.8% 
and 26.9% of vaccinated children, respectively) during the 2013–14 vaccination period 
(Figure 2).
Discussion
This is the first report of population-based, provider-verified data describing the use of 
LAIV among children in the United States. From 2008 to 2014, the percentage of children 
2–8 years of age vaccinated for influenza who received LAIV has nearly doubled (from 
20.1% to 38.0%). The increase in proportional use of LAIV was similar among children age 
9–12 years, although the percentage of children receiving any influenza vaccine was lower 
in this older age group. In North Dakota and Minnesota, at least 50% of children 2–8 years 
of age who received an influenza vaccination during the 2013–14 influenza vaccination 
period exclusively received LAIV, indicating that for some states, LAIV is no longer the less 
frequently administered formulation. Documenting uptake of LAIV in the United States is 
important since this formulation is more effective than IIV among young healthy children [2, 
3], and LAIV usage will likely increase as a result of an ACIP preferential recommendation 
[1]. This report describes increasing use of LAIV prior to the June 25, 2014 
recommendation, and thus future studies seeking to measure the impact of the 
recommendation should consider this preexisting trend. The ACIP position could influence 
patient or parent preferences for age groups beyond those specified in the recommendation, 
and thus monitoring use of LAIV in additional age groups is warranted to monitor potential 
impacts.
IIV remains recommended for healthy children aged 6 months to less than two years, and for 
certain persons ineligible for LAIV; contraindications and precautions for LAIV include 
immunosuppression, egg allergy, asthma, pregnancy, and receipt of certain drugs including 
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aspirin antiviral medications [1]. IIV should be administered to eligible children who present 
for care during encounters in which LAIV is unavailable, which could occur for providers 
that placed IIV orders for the 2014–15 influenza season prior to ACIP’s preferential 
recommendation; ACIP notes that vaccination should not be delayed in such instances. 
Uptake is thus influenced by programmatic factors, and the American Academy of 
Pediatrics has described a need for research on the health services components that influence 
influenza vaccine usage [8]. Purchasing decisions might be affected by price, which is 
higher for LAIV compared with IIV, although one study found LAIV to be more cost 
effective when administered to healthy children 24–59 months of age due to greater 
reduction of illness and associated healthcare costs [9]. Additionally, shelf life, storage 
requirements, and availability from manufacturers, might influence programmatic choices 
between formulations, and differences between public influenza vaccination programs could 
potentially contribute to geographic variability in LAIV uptake. These factors should be 
investigated in order to optimize coverage and inform policy makers considering 
preferentially recommending LAIV to young children.
This report demonstrates that overall coverage with ≥1 dose of influenza vaccine is generally 
increasing among children 2–12 years of age. For some children, ACIP recommends two 
doses of influenza vaccine, depending on age, vaccination history, and influenza season, and 
the proportion of the population that is fully vaccinated for influenza is likely lower than the 
coverage described in this report. IIS sentinel site data are not necessarily nationally 
representative, although increasing use of LAIV among all sites suggests a generalized 
trend. Moreover, a previous analysis examined influenza vaccination records in an area that 
largely overlapped with the jurisdiction of our analysis, and found that trends in influenza 
vaccine coverage in the examined area were comparable to national survey data [10]. These 
provider-verified IIS data allow for timely assessments in selected populations and can 
identify coverage issues warranting further study or intervention. IIS do not universally 
collect in-depth demographic data on vaccinated children, and this limitation prevented 
analysis of predictors of LAIV usage. Exploration of factors that influence relative and 
absolute uptake of LAIV could be useful to inform influenza vaccination programs and 
future policy regarding preferential use of vaccine formulations. Our results indicate 
increasing use of LAIV among younger children in the United States, demonstrating broad 
acceptability of the formulation. Implementation of ACIP’s recommendation is thus 
supported by a preexisting trend of increasing use of LAIV, and this underlying factor 
should be considered when evaluating the impact of the ACIP’s preferential 
recommendation for use of LAIV.
Acknowledgments
We acknowledge the contributions of the following individuals: Rachel Potter, DVM, MS1; Beatrice Salada1; 
Karen E. White, MPH2; Emily Emerson2; Molly Howell, MPH3; Mary Woinarowicz, MA3; Vikki Papadouka, 
PhD, MPH4; Alexandra Ternier, MPH4; Andrew Osborn, MBA5; Mary Beth Kurilo, MPH5; Thomas Maerz6; and 
Stephanie Schauer, PhD6; and Liping Zhu, MD, MPH7.
1Michigan Department of Community Health
2Minnesota Department of Health
3North Dakota Department of Health
Rodgers et al. Page 4
Vaccine. Author manuscript; available in PMC 2018 March 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4New York City Department of Health and Mental Hygiene
5Oregon Health Authority
6Wisconsin Department of Health Services
7Immunization Information Systems Support Branch, Immunization Services Division, Centers for Disease Control 
and Prevention
References
1. Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, et al. Prevention and control 
of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization 
Practices (ACIP) – United States, 2014-15 influenza season. MMWR Morbidity and mortality 
weekly report. 2014; 63:691–7. [PubMed: 25121712] 
2. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated 
versus inactivated influenza vaccine in infants and young children. The New England journal of 
medicine. 2007; 356:685–96. [PubMed: 17301299] 
3. Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, et al. Superior relative 
efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young 
children with recurrent respiratory tract infections. The Pediatric infectious disease journal. 2006; 
25:870–9. [PubMed: 17006279] 
4. Bhatt P, Block SL, Toback SL, Ambrose CS. A prospective observational study of US in-office 
pediatric influenza vaccination during the 2007 to 2009 influenza seasons: use and factors 
associated with increased vaccination rates. Clinical pediatrics. 2010; 49:954–63. [PubMed: 
20522609] 
5. Universally Recommended Vaccinations: Immunization Information Systems. Community 
Preventive Services Task Force. 
6. Centers for Disease C, Prevention. Progress in immunization information systems - United States, 
2012. MMWR Morbidity and mortality weekly report. 2013; 62:1005–8. [PubMed: 24336133] 
7. CDC. Seasonal influenza vaccination coverage among children aged 6 months-18 years – eight 
immunization information system sentinel sites, United States, 2009-10 influenza season. Morbidity 
and mortality weekly report. 2010; 59:1266–9. [PubMed: 20930704] 
8. Committee on infectious d. Recommendations for prevention and control of influenza in children, 
2013-2014. Pediatrics. 2013; 132:e1089–104. [PubMed: 23999962] 
9. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, et al. Cost-effectiveness of live 
attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 
months in the United States. Vaccine. 2008; 26:2841–8. [PubMed: 18462851] 
10. Lu PJ, Santibanez TA, Williams WW, Zhang J, Ding H, Bryan L, et al. Surveillance of influenza 
vaccination coverage–United States, 2007-08 through 2011-12 influenza seasons. Morbidity and 
mortality weekly report Surveillance summaries. 2013; 62:1–28.
Rodgers et al. Page 5
Vaccine. Author manuscript; available in PMC 2018 March 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rodgers et al. Page 6
Vaccine. Author manuscript; available in PMC 2018 March 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Uptake of Influenza Vaccine among children 2–12 years of age (A) and Use of LAIV 
Compared with IIV among Children Receiving Influenza Vaccine (B) — 2008–2014
Data obtained from Immunization Information System sentinel sites located in Michigan, 
Minnesota, North Dakota, New York City, Oregon, and Wisconsin. Collectively, a mean of 
1,179,788 children aged 2–12 years were reported as annually vaccinated for influenza. 
Children who received ≥1 dose of any influenza vaccine are reported among Census 
populations for each influenza vaccination period during 2008–14 (A) and the relative use of 
each formulation among vaccinated children is reported (B).
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Figure 2. Relative Uptake of LAIV among Children Aged 2–8 Years Receiving Influenza Vaccine 
by Immunization Information System Sentinel Sites — 2008–2014
The percentage of pediatric LAIV recipients was defined as the number of 2–8 year olds 
who received one or more doses of LAIV without IIV or unknown formulations, among 
children who received any influenza vaccine of any formulation.
Rodgers et al. Page 8
Vaccine. Author manuscript; available in PMC 2018 March 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
